BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17412838)

  • 1. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase.
    Hazra S; Batra RK; Tai HH; Sharma S; Cui X; Dubinett SM
    Mol Pharmacol; 2007 Jun; 71(6):1715-20. PubMed ID: 17412838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells.
    Hazra S; Dubinett SM
    Prostaglandins Leukot Essent Fatty Acids; 2007 Jul; 77(1):51-8. PubMed ID: 17697767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1.
    Subbaramaiah K; Howe LR; Zhou XK; Yang P; Hudis CA; Kopelovich L; Dannenberg AJ
    Cancer Prev Res (Phila); 2012 Oct; 5(10):1183-94. PubMed ID: 22787115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of prostaglandin transport and metabolism augment protease-activated receptor-2-mediated increases in prostaglandin E2 levels and smooth muscle relaxation in mouse isolated trachea.
    Henry PJ; D'Aprile A; Self G; Hong T; Mann TS
    J Pharmacol Exp Ther; 2005 Sep; 314(3):995-1001. PubMed ID: 15937152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.
    Higashi Y; Holder K; Delafontaine P
    J Biol Chem; 2010 Nov; 285(47):36361-8. PubMed ID: 20843793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-4 regulates COX-2 and PGE2 production in human non-small cell lung cancer.
    Cui X; Yang SC; Sharma S; Heuze-Vourc'h N; Dubinett SM
    Biochem Biophys Res Commun; 2006 May; 343(4):995-1001. PubMed ID: 16574063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells.
    Moore AE; Greenhough A; Roberts HR; Hicks DJ; Patsos HA; Williams AC; Paraskeva C
    Carcinogenesis; 2009 Oct; 30(10):1796-804. PubMed ID: 19638428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway.
    Kapoor M; Kojima F; Qian M; Yang L; Crofford LJ
    J Biol Chem; 2007 Feb; 282(8):5356-66. PubMed ID: 17186945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer.
    Ding Y; Tong M; Liu S; Moscow JA; Tai HH
    Carcinogenesis; 2005 Jan; 26(1):65-72. PubMed ID: 15358636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2.
    Kempná P; Hofer G; Mullis PE; Flück CE
    Mol Pharmacol; 2007 Mar; 71(3):787-98. PubMed ID: 17138841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARγ agonists target aromatase via both PGE2 and BRCA1.
    Margalit O; Wang D; Dubois RN
    Cancer Prev Res (Phila); 2012 Oct; 5(10):1169-72. PubMed ID: 23041473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
    Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
    Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail.
    Choudhary R; Li H; Winn RA; Sorenson AL; Weiser-Evans MC; Nemenoff RA
    Neoplasia; 2010 Mar; 12(3):224-34. PubMed ID: 20234816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophages programmed by apoptotic cells promote angiogenesis via prostaglandin E2.
    Brecht K; Weigert A; Hu J; Popp R; Fisslthaler B; Korff T; Fleming I; Geisslinger G; Brüne B
    FASEB J; 2011 Jul; 25(7):2408-17. PubMed ID: 21450910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB.
    Bren-Mattison Y; Meyer AM; Van Putten V; Li H; Kuhn K; Stearman R; Weiser-Evans M; Winn RA; Heasley LE; Nemenoff RA
    Mol Pharmacol; 2008 Mar; 73(3):709-17. PubMed ID: 18055759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinediones increase arachidonic acid release and subsequent prostanoid production in a peroxisome proliferator-activated receptor gamma-independent manner.
    Tsukamoto H; Hishinuma T; Suzuki N; Tayama R; Hiratsuka M; Yoshihisa T; Mizugaki M; Goto J
    Prostaglandins Other Lipid Mediat; 2004 Apr; 73(3-4):191-213. PubMed ID: 15287152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells.
    Smartt HJ; Greenhough A; Ordóñez-Morán P; Talero E; Cherry CA; Wallam CA; Parry L; Al Kharusi M; Roberts HR; Mariadason JM; Clarke AR; Huelsken J; Williams AC; Paraskeva C
    Gut; 2012 Sep; 61(9):1306-14. PubMed ID: 22082586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents.
    Cho H; Tai HH
    Prostaglandins Leukot Essent Fatty Acids; 2002 Dec; 67(6):461-5. PubMed ID: 12468268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.
    Otani T; Yamaguchi K; Scherl E; Du B; Tai HH; Greifer M; Petrovic L; Daikoku T; Dey SK; Subbaramaiah K; Dannenberg AJ
    Am J Physiol Gastrointest Liver Physiol; 2006 Feb; 290(2):G361-8. PubMed ID: 16195422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin catabolic enzymes as tumor suppressors.
    Tai HH
    Cancer Metastasis Rev; 2011 Dec; 30(3-4):409-17. PubMed ID: 22020925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.